Coherus Oncology (CHRS) Acquisitions (2014)

Coherus Oncology (CHRS) reported Acquisitions of $2.3 million for Q1 2014.

Coherus Oncology (CHRS) Acquisitions (2014) Analysis & Trends

Coherus Oncology (CHRS) has 1 years of Acquisitions data on file, last reported at $2.3 million in Q1 2014.

For the quarter ending Q1 2014, Acquisitions changed N/A year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2014 stood at $2.3 million (changed N/A YoY), and the FY2023 full-year result was $7.0 million, changed N/A from the prior year.
Acquisitions held at $2.3 million in Q1 2014.
In the past five years, Acquisitions ranged from a high of $2.3 million in Q1 2014 to a low of $2.3 million in Q1 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Coherus Oncology	195.05 Mn	28.00 Mn	8.50 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2014	2.33 Mn